Wird geladen...
Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
A typical biosimilar study in oncology uses the overall response evaluated at a specific time point as the primary endpoint, which is generally acceptable regulatorily, to assess clinical equivalence between a biosimilar and its reference product. The standard primary endpoint for evaluating an anti...
Gespeichert in:
| Veröffentlicht in: | JNCI Cancer Spectr |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7050006/ https://ncbi.nlm.nih.gov/pubmed/32337484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkz058 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|